Leramistat failed to meet its primary endpoint of improving tender and swollen joints in moderate-to-severe rheumatoid arthritis patients resistant to methotrexate treatment.
Phase 2b trial of leramistat demonstrates significant reduction in bone erosions and improvements in disability and fatigue for rheumatoid arthritis patients, despite not meeting ACR20 primary endpoint.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.